Health Care & Life Sciences » Biotechnology | Genetic Technologies Ltd.

Genetic Technologies Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
4,564.30
2,011.90
824.60
518.50
189.30
Cost of Goods Sold (COGS) incl. D&A
2,049.20
1,067.60
1,072.90
792.90
538.00
Gross Income
2,515.00
944.30
248.30
274.40
348.70
SG&A Expense
13,590.50
11,838.00
8,974.40
7,721.00
6,183.20
EBIT
11,075.50
10,893.70
9,222.70
7,995.40
6,531.90
Unusual Expense
352.80
446.30
-
544.70
-
Non Operating Income/Expense
1,926.30
2,643.40
336.80
155.70
626.60
Interest Expense
744.20
264.70
-
-
-
Pretax Income
10,130.20
8,921.40
8,818.80
8,657.00
5,763.20
Income Tax
358.40
111.20
359.80
253.20
299.40
Equity in Affiliates
362.70
-
-
-
-
Consolidated Net Income
10,134.50
8,810.20
8,459.00
8,403.80
5,463.90
Net Income
10,125.20
8,810.20
8,459.00
8,403.80
5,463.90
Net Income After Extraordinaries
10,125.20
8,810.20
8,459.00
8,403.80
5,463.90
Net Income Available to Common
10,125.20
8,810.20
8,459.00
8,403.80
5,463.90
EPS (Basic)
0.02
0.01
0.00
0.00
0.00
Basic Shares Outstanding
574,557.70
1,072,803.40
1,715,214.20
2,121,638.90
2,435,282.70
EPS (Diluted)
0.02
0.01
0.00
0.00
0.00
Diluted Shares Outstanding
574,557.70
1,072,803.40
1,715,214.20
2,121,638.90
2,435,282.70
EBITDA
10,737.00
10,661.50
8,832.60
7,623.80
6,228.20
Non-Operating Interest Income
116.00
40.00
67.10
38.80
15.20
Minority Interest Expense
9.30
-
-
-
-

About Genetic Technologies

View Profile
Address
60-66 Hanover Street
Fitzroy Victoria (VIC) 3065
Australia
Employees -
Website http://www.gtgcorporate.com
Updated 07/08/2019
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.